T his special miniseries on cancer includes two reviews. The first one, by Drs François Ghiringhelli and Lionel Apetoh, analyzes the impact of 5-fluorouracil (5-FU) on anticancer immune responses. [1] The second review, by Drs. Michael Burns, Brandon Leonard, and Reuben Harris, describes the properties of the DNA cytosine deaminase, APOBEC3B, which converts cytosine to uracil and may be responsible for various mutations in human cancers. [2] In the first review, "Enhancing the anticancer effects of 5-fluorouracil: Current challenges and future perspectives," Drs Ghiringhelli and Apetoh describe the biological mechanisms stimulated by 5-FU to potentiate anticancer immune responses. In the second review entitled "APOBEC3B: Pathological consequences of an innate immune DNA mutator," the authors introduce the APOBEC family and describe the physiological functions of APOBEC3 members in innate immunity. Using a very good iconography, the authors depict the enzymatic activity of APOBEC members, which catalyze the hydrolysis of cytosine to uracil in single-stranded DNA, and the potential mutagenic outcomes of uracil lesions. The authors analyze the evidence showing that APOBEC3B is involved in human cancer and the impact of this enzyme in promoting genetic heterogeneity. Finally, the authors present the results from different groups suggesting that APOBEC3B overexpression and mutagenesis are stimulated by an antiviral response against the human papillomavirus in cervical and head/neck cancers. This review suggests that increasing or decreasing APOBEC3B mutagenesis in APOBEC3B-expressing cells may stimulate tumor cell death through various mechanisms.
These two complementary reviews thus highlight the importance of chemotherapy or enzymes targeting DNA or RNA integrity in strategies to eradicate cancer growth.
